The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kite, a Gilead Company
Favorable tumor immune microenvironment (TME) and robust chimeric antigen receptor (CAR) T-cell expansion may overcome tumor burden (TB) and promote durable efficacy with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).
 
Justin Chou
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Five Prime Therapeutics; Gilead Sciences
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Vicki Plaks
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Kite, a Gilead Company
Patents, Royalties, Other Intellectual Property - Genentech
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Soumya Poddar
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
Patents, Royalties, Other Intellectual Property - UCLA
 
Zixing Wang
Employment - Kite, a Gilead Company; Seagen
Stock and Other Ownership Interests - Gilead Sciences; Seagen
 
Frederick Lundry Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Calibr; Celgene; Cellular Biomedicine Group; Cowen; EcoR1 Capital; GammaDelta Therapeutics; Gerson Lehrman Group; Iovance Biotherapeutics; Legend Biotech; Novartis; WUGEN, Inc.
Research Funding - Alimera Sciences (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Calibr; Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Legend Biotech; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy; Royalty income from Takeda Pharmaceuticals
Travel, Accommodations, Expenses - Alimera Sciences; Celgene; Chugai Pharma; Kite/Gilead; Legend Biotech; Medscape; Merck; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
 
David Bernard Miklos
Consulting or Advisory Role - Adaptive Biotechnologies; Alimera Sciences; Janssen; Juno/Celgene; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics; Precision Biosciences
Research Funding - Adaptive Biotechnologies; Alimera Sciences; Kite, a Gilead company; Novartis; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Juno Therapeutics; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics/Janssen
 
Caron A. Jacobson
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Humanigen; Kite/Gilead; Nkarta; Novartis; precision biosciences
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Humanigen; Kite/Gilead; Lonza; Nkarta; Novartis; Precision Biosciences
Speakers' Bureau - Axis Bioservices; Clinical Care Options
Research Funding - Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer
Travel, Accommodations, Expenses - Kite/Gilead; Novartis; Precision Biosciences
 
Philippe Armand
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - ADC Therapeutics; Bristol-Myers Squibb; C4 Therapeutics; Celgene; Daiichi Sankyo; Enterome; Epizyme; Genentech/Roche; GenMab; Merck Sharp & Dohme; Miltenyi Biotec; MorphoSys; Regeneron; Tessa Therapeutics
Research Funding - Adaptive Biotechnologies (Inst); Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); igm (Inst); Kite, a Gilead company (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Zahid Bashir
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - OmniacPharmConsult
 
Jérôme Galon
Stock and Other Ownership Interests - HalioDx
Honoraria - Amgen; Bristol-Myers Squibb; CatalYm; HalioDx; Illumina; IO Biotech; Lunaphore Technologies; Merck Serono; Merck Sharp & Dohme; Northwest Biotherapeutics
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; CatalYm; HalioDx; Illumina; IO Biotech; Lunaphore Technologies; Merck Serono; Merck Sharp & Dohme; Northwest Biotherapeutics
Research Funding - AstraZeneca; ImCheck Therapeutics; IO Biotech; Janssen; MedImmune; Perkin Elmer
Patents, Royalties, Other Intellectual Property - Inserm
 
John M. Rossi
No Relationships to Disclose
 
Adrian Bot
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences